Pipeline

Mersana’s innovative platforms are a highly efficient product engine that is building a robust discovery pipeline for us and our partners. Our ADCs in preclinical and clinical trials are first-in-class molecules that target multiple tumor types with high unmet medical need. We believe our platforms create an opportunity for our ADCs to demonstrate improved safety and efficacy relative to ADCs developed using first-generation technology. Our lead asset, upifitamab rilsodotin (UpRi), is a first-in-class Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration study in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1 umbrella study in combination with other ovarian cancer therapies. XMT-1592, our second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).

ADC ProgramTargetIndicationPlatformDiscoveryPreclinicalP1P1P2P3
Clinical
upifitamab
rilsodotin (UpRi)*
NaPi2b
Platinum-Resistant Ovarian Cancer Dolaflexin
XMT-1536*
NaPi2b
Platinum-Resistant Ovarian Cancer Dolaflexin
XMT-1536*
NaPi2b
Recurrent Platinum-Sensitive Ovarian Cancer Maintenance Dolaflexin
Preclinical
XMT-1592*
NaPi2b
Ovarian Cancer NSCLC Adenocarcinoma Dolasynthen
Discovery
XMT-1660
B7-H4
Multiple Solid Tumors Dolasynthen
XMT-2056
HER2
Undisclosed Immunosynthen
XMT-2068
Tumor-Associated Antigen
Undisclosed Immunosynthen
XMT-2175
Tumor-Associated Antigen
Undisclosed Immunosynthen
Multiple Programs
Undisclosed
Undisclosed Immunosynthen Dolasynthen Dolaflexin
Platform Collaborations
Multiple
Multiple
Undisclosed Dolaflexin
ASN004
5T4
Undisclosed Dolaflexin
DrugIndicationStage
Clinical
upifitamab
rilsodotin (UpRi)*
NaPi2b
Platinum-Resistant Ovarian Cancer DolaflexinP1
XMT-1536*
NaPi2b
Platinum-Resistant Ovarian Cancer DolaflexinPreclinical
XMT-1536*
NaPi2b
Recurrent Platinum-Sensitive Ovarian Cancer Maintenance DolaflexinP1
Preclinical
XMT-1592*
NaPi2b
Ovarian Cancer NSCLC Adenocarcinoma DolasynthenPreclinical
Discovery
XMT-1660
B7-H4
Multiple Solid Tumors DolasynthenDiscovery
XMT-2056
HER2
Undisclosed ImmunosynthenDiscovery
XMT-2068
Tumor-Associated Antigen
Undisclosed ImmunosynthenDiscovery
XMT-2175
Tumor-Associated Antigen
Undisclosed ImmunosynthenDiscovery
Multiple Programs
Undisclosed
Undisclosed Immunosynthen Dolasynthen Dolaflexin
Platform Collaborations
Multiple
Multiple
Undisclosed DolaflexinDiscovery
ASN004
5T4
Undisclosed DolaflexinDiscovery
ADC Program Target Indication Platform Phase
upifitamab
rilsodotin (UpRi)*
NaPi2b Platinum-Resistant Ovarian Cancer Dolaflexin P2 Pivotal Study
upifitamab
rilsodotin (UpRi)*
NaPi2b Platinum-Resistant Ovarian Cancer Dolaflexin P1 Dose Escalation
upifitamab
rilsodotin (UpRi)*
NaPi2b Recurrent Platinum-Sensitive Ovarian Cancer Maintenance Dolaflexin P3
XMT-1592* NaPi2b Ovarian Cancer NSCLC Adenocarcinoma Dolasynthen P1 Dose Escalation
XMT-1660 B7-H4 Multiple Solid Tumors Dolasynthen Preclinical
XMT-2056 HER2 Undisclosed Immunosynthen Preclinical
XMT-2068 Tumor-Associated Antigen Undisclosed Immunosynthen Discovery
XMT-2175 Tumor-Associated Antigen Undisclosed Immunosynthen Discovery
Multiple Programs Undisclosed Undisclosed Immunosynthen Preclinical
Multiple Programs Undisclosed Undisclosed Dolasynthen or Dolaflexin Discovery
Multiple
EMD Logo
Multiple Undisclosed Dolaflexin Preclinical
ASN004
Asana Logo
5T4 Undisclosed Dolaflexin P1 Dose Escalation

*NaPi2b antibody used in UpRi (formerly XMT-1536) and XMT-1592 is in-licensed from Recepta Biopharma. Recepta has rights to commercialize UpRi and XMT-1592 in Brazil.